Cracks in the facade: Is pharma's pandemic ‘feel good factor’ waning?
The discordant effects of the Covid-19 pandemic on pharma reputation continues. While the overall industry still retains a respectable halo from its Covid-19 quick response and leadership, a new patient group study reveals a different story emerging in the details.
On one hand, US patient advocacy groups rated the industry higher-than-ever overall. More than two-thirds (67%) of groups gave the industry a thumbs up for 2021, a whopping 10 percentage point increase over the year before, according to the PatientView annual study, now in its 9th year.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,900+ biopharma pros reading Endpoints daily — and it's free.